Singapore, June 24 -- Apeloa Pharmaceutical, a subsidiary of Hengdian Group, is a leadingChinese and global pharmaceutical firm and a key exhibitor at CPHI China.
Apeloa's business spans fourmain areas: active pharmaceutical ingredients(APls),contract development andmanufacturing organization (CDMO), finished dosage form(FDF) and aesthetics & careingredients (ACl). In 2024,Apeloa achieved sales revenue of RMB 11.97 billion (USD 1.7billion). Apeloa invests over 5% of its annual revenue into R&D each year.
Apeloa Pharmaceutical's core mission is to use technology for health,to bring innovationand cost efficiency to all clients. Apeloa's team comprises over 7000 employees, including1300 scientists.It ranks top 2 APl exporters and top 5 CDMO ...